Terns Pharmaceuticals Net Income vs. Debt To Equity
| TERN Stock | USD 44.33 1.51 3.53% |
Net Loss | First Reported 2019-12-31 | Previous Quarter -24.1 M | Current Value -24.6 M | Quarterly Volatility 6.9 M |
The module aggregates profitability drivers for Terns Pharmaceuticals with ratios tied to revenue, assets, and equity.
World Market Map. Understanding Terns Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Terns accounting equity. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. Market prices can move with sentiment and macro cycles, creating divergence from fundamentals. The valuation process compares these measures for perspective.
The concept of value for Terns Pharmaceuticals differs from its quoted price, since each reflects a different lens. Reviewing financial results, valuation ratios, and competitive positioning helps frame the value discussion. Trading price represents the transaction level agreed by market participants.
Terns Pharmaceuticals Debt To Equity vs. Net Income Fundamental Analysis
Peer-based valuation metrics position Terns Pharmaceuticals within its sector hierarchy. Terns Pharmaceuticals is evaluated as third in Net Income in net income category among its top compatitors. It is rated below average. in debt to equity category among its top compatitors . Comparative financial data indicate that Net Loss is shifting by roughly 4.76%. Previously, Net Loss was valued at -79.97 Million. Relative ratio analysis evaluates Terns Pharmaceuticals's earnings valuation.Terns Debt To Equity vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Terns Pharmaceuticals |
| = | -88.85 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Terns Pharmaceuticals |
| = | 0.01 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Terns Debt To Equity Comparison
Terns Pharmaceuticals is currently under evaluation. in debt to equity category among its top compatitors.
Terns Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Terns Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Terns Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Terns Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Terns Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -251.1 K | -263.7 K | |
| Net Interest Income | 15.3 M | 16 M | |
| Interest Income | 15.3 M | 16 M | |
| Operating Income | -91.7 M | -96.3 M | |
| Net Loss | -80 M | -84 M | |
| Income Before Tax | -79.7 M | -83.7 M | |
| Total Other Income Expense Net | 15.3 M | 16 M | |
| Net Loss | -54.3 M | -57 M | |
| Net Loss | -80 M | -84 M | |
| Income Tax Expense | 299 K | 328.6 K | |
| Non Operating Income Net Other | 1.8 M | 1.6 M | |
| Change To Netincome | 12.4 M | 13 M | |
| Net Loss | -1.01 | -1.06 | |
| Income Quality | 0.91 | 0.92 | |
| Net Income Per E B T | 0.90 | 0.80 |
Terns Profitability Driver Comparison
Understanding Terns Pharmaceuticals' profitability drivers is a critical part of evaluating Terns Pharmaceuticals as an investment. Unexpected events - from regulatory changes to commodity price movements - can materially alter the profit trajectory and investment outlook during any given holding period.
Terns Pharmaceuticals Earnings Estimation Breakdown
Based on trailing twelve-month earnings reporting, analysts project Terns Pharmaceuticals' next EPS at -0.2875. The range of analyst estimates extends from -0.34 on the low end to -0.22 on the high end for Terns Pharmaceuticals. Non-recurring items are excluded from this projection to ensure that the estimate reflects sustainable earnings capacity.Last Reported EPS
-0.34 Lowest | Expected EPS | -0.22 Highest |
Terns Pharmaceuticals Earnings Projection Consensus
A consensus EPS-based fair value estimate above Terns Pharmaceuticals' current market price may suggest the stock is trading below intrinsic value by some metrics. An estimate below market price raises questions about whether the current valuation is sustainable without stronger earnings growth. Both interpretations are scenario-based and should be paired with fundamental due diligence and risk assessment before allocation.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 11 | 50.0% | 0.0 | -0.2875 | -1.02 |
Terns Pharmaceuticals Earnings per Share Projection vs Actual
The distinction between actual and expected EPS for Terns Pharmaceuticals is foundational to earnings analysis. Actual EPS is confirmed at the close of each reporting cycle; expected EPS is the analyst consensus formed before reporting. Higher EPS is generally associated with stronger profitability, and the weighted average methodology ensures fairness when share counts fluctuate.Terns Pharmaceuticals Estimated Months Earnings per Share
Income-focused investors in Terns Pharmaceuticals use EPS trends as a proxy for dividend sustainability and future payout growth. Rising EPS supports the ability to maintain or increase distributions; declining EPS may signal payout risk. For best results, EPS should be evaluated alongside payout ratio, free cash flow, and peer comparisons.Terns Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises represent the gap between what Terns Pharmaceuticals reports and what the analyst community projected - a gap that markets price rapidly and often decisively. Both the direction and magnitude of the surprise influence the near-term trend after results are published. Analyst EPS estimates are built from guidance, sector trends, and detailed financial models updated throughout the quarter.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-10 | 2025-09-30 | -0.3021 | -0.27 | 0.0321 | 10 | ||
2025-08-05 | 2025-06-30 | -0.2918 | -0.26 | 0.0318 | 10 | ||
2025-05-12 | 2025-03-31 | -0.2702 | -0.26 | 0.0102 | 3 | ||
2025-03-12 | 2024-12-31 | -0.3002 | -0.24 | 0.0602 | 20 | ||
2024-11-12 | 2024-09-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-08-05 | 2024-06-30 | -0.34 | -0.31 | 0.03 | 8 | ||
2024-05-13 | 2024-03-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2024-03-14 | 2023-12-31 | -0.29 | -0.29 | 0.0 | 0 | ||
2023-11-14 | 2023-09-30 | -0.31 | -0.42 | -0.11 | 35 | ||
2023-08-08 | 2023-06-30 | -0.34 | -0.25 | 0.09 | 26 | ||
2023-05-15 | 2023-03-31 | -0.27 | -0.31 | -0.04 | 14 | ||
2023-03-27 | 2022-12-31 | -0.43 | -0.29 | 0.14 | 32 | ||
2022-11-09 | 2022-09-30 | -0.52 | -0.44 | 0.08 | 15 | ||
2022-08-08 | 2022-06-30 | -0.59 | -0.55 | 0.04 | 6 | ||
2022-05-16 | 2022-03-31 | -0.64 | -0.55 | 0.09 | 14 | ||
2022-03-03 | 2021-12-31 | -0.63 | -0.56 | 0.07 | 11 | ||
2021-11-15 | 2021-09-30 | -0.6 | -0.47 | 0.13 | 21 | ||
2021-08-16 | 2021-06-30 | -0.71 | -0.43 | 0.28 | 39 | ||
2021-05-14 | 2021-03-31 | -0.77 | -0.88 | -0.11 | 14 | ||
2021-03-30 | 2020-12-31 | -0.91 | -30.94 | -30.03 | 3300 |
Use Terns Pharmaceuticals in pair-trading
Pair trading with Terns Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Terns Pharmaceuticals Pair Trading
Terns Pharmaceuticals Pair Trading Analysis
Identifying correlated replacements for Terns Pharmaceuticals is particularly important in concentrated portfolios where Terns Pharmaceuticals represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Terns Pharmaceuticals it is a practical tool. High correlations between Terns Pharmaceuticals and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Correlation analysis and pair evaluation for Terns Pharmaceuticals can support hedging context. The method can be applied across sectors and broader equity sets.Use Investing Themes to Complement your Terns Pharmaceuticals position
Using Terns Pharmaceuticals inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Advertising Thematic Idea Now
Advertising
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for Terns Stock Analysis
Reviewing Terns Pharmaceuticals commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Terns Stock:World Market Map. Our How to Buy Terns Stock guide explains the steps to invest in Terns Pharmaceuticals stock.Analysis related to Terns Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
A projection view for Terns Pharmaceuticals starts with historical financial statements. The core view includes income statement, balance sheet, and cash flow.